Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities
Dina Alramadhani(Virginia Commonwealth University), Martin K. Safo(Virginia Commonwealth University), Osheiza Abdulmalik(Children's Hospital of Philadelphia), B. Daniel Pierce(Children's Hospital of Philadelphia), Anfal S. Aljahdali(King Abdulaziz University)
Cited by 8
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
|Science|2018|159
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression
|Journal of Clinical Investigation|2014|125